Synopsis Migraine or severe headache has become a common neurological disorder in the modern world. The acute onset of severe headache eventually develops into a chronic migraine (CM) that causes a disabling effect on the patient’s life. CM significantly affects work productivity, impacts social and psychological behavior, and reduces health-related quality of life (HRQoL). What was the need for the study? Erenumab, a human anti-canonical calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, showed the potential in preventing CM pain.
Therefore, the study was necessary to assess the clinical efficacy and safety of erenumab in patients with CM. This Journal Watch presents a summary of a clinical study titled “ Erenumab In Chronic Migraine ” from the journal “ American Academy Of Neurology. ” Authors: Richard B. Lipton, MD, Stewart J. Tepper, MD, Uwe Reuter, MD, et al.…
